Replies to post #669204 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Let’s see.

I was right in my opinion that the trial would reach statistical significance for survival.

I was right that NWBO would be able to demonstrate a method of action with remarkable depth and breadth.

I was right that LP, Dr.Bosch, Dr.Liau, Dr. Prins and others were correct in their assessment early on that single peptide and/or limited multi-antigenic peptide therapies were inferior to autologous Tumor lysate pulsed dendritic cell therapy.

I was right the mRNA DC company Argos used an inferior methodology and quantity which ultimately failed according to their owners.

I was right that Dr. Weller and Dr. Sampson were incorrect in there assessment that rhindopepimut could prevent tumor escape, and I was also right that imuc and Celldex ignored some possible applications for their therapies after they failed their endpoints.

I was right that Optune long term survival is
too censored and too extrapolatory to claim its five year survival numbers, and in fact, it looked like long term survival was decaying when they stopped any further follow up.

I was right that DCVax-l would be written up in a top tier journal with a strong conclusion correlating DCVax-l with survival.

I was right that NWBO paid attention to research which shows smaller vaccine doses prevent hypoxia and in fact promote dc migration.

I was right that NWBO researchers were correct that intradermal injection that NWBO uses is the most effective administration route for DCVax-l.

I was correct that researchers were correct that Temodar slows or inhibits t-cells’ ability to fight cancer.

I was right years ago that researchers were correct in their assessment that poly-iclc would enhance DCVax-l.

I was likely right to point out (back in 2015) Dr. Prins, Dr. Liau, NWBO and UCLA have likely found a future near cure when appropriately combining DCVax-l with plx-3397, poly-iclc and perhaps CI (when necessary).

I was right that NWBO would reach data lock.

I was right that NWBO would likely publish successful results in a top tier journal.

I was right that NWBO would likely submit an maa to MHRA before the end of this year.

I’m probably right it will be accepted the first go around.

I’m probably right it will be approved in multiple jurisdictions.

I’m probably right that at least one approval will occur in 2024.

I was right that Cognate and Advent would become commercially licensed via their manufacturing DCVax-l.

I was right when I suggested years ago that NWBO should use as much of the tumor as possible, and not just a cubic centimeter, because heterogeneity varies not only between tumors but on any one tumor itself. Although I’m sure they probably knew this already.

So despite being wrong about many timing issues in the past, (as were many of us) I have been right and may continue to be right on many substantial assertions listed above and many others not herein listed)